The increasing drug prices in Europe

Vytenis Andriukaitis

Vytenis Andriukaitis, Member of the EC in charge of Health and Food Safety, and Carlos Moedas, Member of the EC in charge of Research, Science and Innovation, awarded the “Horizon Prize – Better Use of Antibiotics” and “The EU Health Awards for NGO’s fighting Antimicrobial Resistance” at a ceremony hold in Leuven. © European Union , 2017 / Source: EC – Audiovisual Service / Photo: Lukasz Kobus.

This article was written by one of our passionate readers, Mrs Rachel Everly. The opinions expressed within reflect only the writer’s views and not The European Sting’s position on the issue.

Rising drug prices have not been a recent issue, it has always been a part and parcel of the medical expenses. Not only is the United States suffering through a spike in the prices of medicines, but European medical bills have taken a toll for the worse as well. Prior to that, Europe had refrained from huge raises in the prices and until 2011, the selling price of many prescription pills had been steadily low.

Since most of the European nations are funding the healthcare systems on a government level, it is only understandable that they would want to keep a close track of the pharmaceutical industry. Due to this reason, the European Pharmaceutical companies are known to work on laws and regulations that restrict them from increasing the prices of the medicines for more than once a year. The price, profits, and comparison of the prices with the international market were always screened and assessed throughout the year without adjusting the prices.

In 2011, many European countries saw a gradual rise in multiple medicines and the rates have been rising ever since, without any restriction. This will affect many consumers and the fee structure of their individual health plans. To counter this problem, European Parliament’s environment Committee (ENVI) is favoring a non-legislative proposition that will strive for making these products more widespread in the European region. However, this must not be confused with an actual law being added in the region’s policies, as it is merely a resolution waiting to be approved by the authorities. With time, it may be considered and the European Union may only then choose to implement it.

The price of specific drugs has been a matter of huge concern for the public. Looking at the prices of those medicines in the previous years has shown an increase in prices for as much as over 1000%. Drugs that are used for leukemia patients have an increased price of 1225%, while tamoxifen, which is used primarily for breast cancer has risen by 1080% from 2011 to 2016. A chemotherapy drug has seen a spike of 1500% but later was fined for 5 million euros for an illegal increase in the price.

Charges of relatively new drugs that have little to no competition are also in the race for increasing their prices up to stupendous amounts. Multiple Sclerosis and Cancer treatment drugs are hiking due to lack of competition and insurance companies and pharmacy beneficiaries are losing against keeping these companies at bay.

The setting not only destabilizes the people who are insured but deeply affects the people who chose not to be insured or cannot afford healthcare. Previously, a person who could not have afforded to have themselves operated could find comfort in medicines. The same is not the case anymore and medical prescription drugs have become even more unattainable than before for many uninsured people out there. Seniors who have retired and do not have an insurance plan can also be looking at paying higher prices than they have previously been paying.

It has been debated for more than one year that the prices of the drugs do not represent the true cost of its production. It is concluded that the price of its manufacturing is far lower than the price label put on the product.  Most of these increments in prices have more to do with profits for these drug manufacturing companies and little to do with the increasing demands and lack of supply. To counter any research and development aspect of a new drug and decrease its cost, the patient-driven research is promoted. This means that the patient can sponsor the research and have the cure developed and tested.

Another speculation that has also been made is that due to the fact that they are only allowed to raise the costs once a year. This has made the marketers overly cautious and in order to withstand any possible demand and supply problem, or a price hike in the global market, they increase their rates by a huge percentage.

In order to provide a safer and more affordable plan for the healthcare system, the government, the people, and the drug manufacturers must work together. More and more efforts have been put on by EU health ministers in 2016 to warn the pharmaceuticals to lower the prices down as it has created a market that is highly unapproachable.

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Join the Hive!

Featured Stings

Stopping antimicrobial resistance would cost just USD 2 per person a year

CEOs in these countries are more likely to go with their gut

EU’s Mogherini visits Turkey “to step up engagement” and highlight interests

Parliament backs a modernised EU electoral law

EU-US resume trade negotiations under the spell of NSA surveillance

Syria: Civilians caught in crossfire, UN refugee chief urges Jordan to open its border

“China will strive to enhance the performance of economic growth”, President Xi highlights from the World Economic Forum 2017 in Davos

MARKUP initiative to boost market access to Europe for East African SMEs

TTIP 9th Round marked by American disappointment: Will some optimism save this trade agreement?

Cultural diversity can drive economies. Here are lessons from India and South Asia

A Sting Exclusive: “Climate change and youth inaction: oblivion or nonchalance?”, AIESEC wonders from Brussels

The EU Commission implicates major banks in cartel cases, threatens with devastating fines

Biggest London City Banks ready to move core European operations to Frankfurt or Dublin?

Eurozone at risk of home-made deflation and recession

‘Path to peace’ on Korean Peninsula only possible through diplomacy and full denuclearization: US tells Security Council

Our present and future tax payments usurped by banks

Facebook-Cambridge Analytica: MEPs demand action to protect citizens’ privacy

Banks must take bold action to fight climate change. This is how they can do it

EU and India re-open talks over strategic partnership while prepare for a Free Trade Agreement

Somalia: UN urges steps to ensure future elections not ‘marred’ by rights abuses seen in recent polls

3 natural mysteries that could be explained by quantum physics

UN rights chief denounces Burundi for ‘belligerent and defamatory’ attack on inquiry team

Job automation risks vary widely across different regions within countries

Youth and children in Europe set the new perspectives for the decades to come

WEF Davos 2016 LIVE: “If we do not do properly the Paris agreement, then all 16 remaining goals will be undermined”, UN Secretary General Ban Ki-moon cautions from Davos

Nuclear non-proliferation treaty an ‘essential pillar’ of international peace, says UN chief

The G7 should take the lead on ocean targets for 2020

Court of Auditors: EU spending infested with errors well above the materiality threshold of 2%

“Only through energy policy we can trigger competitiveness”. The Sting live from #EBS2015: Energy Union – When will it happen?

The success story of a Chinese investment in the Greek port of Piraeus

Faith can overcome religious nationalism. Here’s how

A day in the life of a refugee: the role of nations and citizens of the world

Young people are not a nameless, faceless mass. So why do we treat them as such?

SPB TV @ MWC14: The TV of the Future

“None of our member states has the dimension to compete with China and the US, not even Germany!”, Head of EUREKA Pedro Nunes on another Sting Exclusive

The creative technology and its advancements

Finland must focus on integrating migrant women and their children to boost their contribution to the economy and society

G20 LIVE: “ISIL is the face of evil; our goal is to degrade and ultimately destroy this barbaric terrorist organisation”, US President Barack Obama cries out from Antalya Turkey

EU citizens disenchanted with Economic and Monetary Union over rising poverty and high unemployment

Hazy ‘breakthrough’ saves PM May, leaves Ireland in limbo: Brexit

India-UN fund gets 22 development projects off the ground in first year

More than one billion people do not have access to electricity. What will it take to get them connected?

The European Internet is not neutral and neither is the Commissioner

The impossible end of the war in Syria

New rules for audiovisual media services approved by Parliament

Facebook has built an AI-based tool that fixes the social network when it crashes

Merkel had it her way with the refugees & immigrants but can Greece and Turkey deliver?

MWC 2016 LIVE: T-Mobile US reveals 5G trial plans

Air quality: Commission takes action to protect citizens from air pollution

Digital distrust: We’re losing faith in technology to solve the world’s problems

What lies ahead for the Korean Peninsula?

Chauvinism and xenophobia will lead to global assertiveness and more wars

VW emissions scandal: While U.S. car owners are vindicated, Europe still unable to change its laws and protect its consumers

Can Greece’s devastating economy deal with the migration crisis?

UN Human Rights Council resolution on youth and human rights: a step forward for youth rights

A very good morning in European markets

The EU Commission lets money market funds continue the unholy game of banks

How wealthy people transmit this advantage to their children and grand children

UN chief welcomes agreement by rival leaders in South Sudan, as a step towards ‘inclusive and implementable’ peace

Ahead of State of the Union the European Youth Forum highlights lack of action on youth employment

What are the real targets of EU’s efforts to fight tax evasion?

More Stings?

Trackbacks

  1. […] The cost of new medical technologies and drugs remains the primary cause of the high rate of medical inflation: this is why a discussion at European level with the European Federation of Pharmaceutical Industries and Associations is still open: drug pricing is at the top of the bill. […]

  2. […] Il costo di nuove tecnologie e medicinali rimane la causa principale dell’aumento dei tassi di inflazione medica: questo è il motivo per cui a livello europeo è in corso una discussione con l’Associazione Europea delle Compagnie Farmaceutiche. Il punto principale dell’agenda è sempre quello: il continuo aumento dei medicinali. […]

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s